They found that, as first-line agents, SGLT2is and GLP-1RAs would improve T2DM outcomes, but their costs would need to fall by at least 70% to be cost-effective [84]
Reduced appetite can make it easier to stay in a calorie deficit, but it can also lead to: poor protein intake lower micronutrient intake dehydration reduced training quality higher fatigue That is why physician-guided peptide therapy is often more effective than following scattered online advice
For some people, pursuing weight loss can be harmful, for instance by leading to weight cycling or increasing the risk of developing an eating disorder
That's not a reason for alarm, but it is a reason coverage decisions and clinical guidelines will keep evolving as the data matures Forbes What's fascinating isn't just the rise in GLP-1 use it's how quickly they're reshaping conversations around obesity
34 The AMPLITUDE-O trial demonstrated significant dose-dependent effects of efpeglenatide on HF hospitalisation in patients with T2D and CVD or renal disease, along with one risk factor
I have only been using this shot for about 3 weeks
)
